price
NN
NASDAQ · NNNN
Anbio Biotechnology Class A Ordinary Shares
Healthcare · Medical - Instruments & Supplies
$5.51
Down-$0.02 (-0.36%)
Updated Sep 16, 2026, 3:35 PM
SID Score
2.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.28B
- P/E ratio
- 480.56
- Dividend yield
- 0.00%
- 52-week range
- $5.25 – $36.11
- Volume
- 275.05K
- Avg. volume
- 48.26K
Price performance
NNNN price history
1M range · 20 trading sessions · Daily adjusted prices
NNNN closed at $5.51 after 20 trading sessions, down 34.01% for the selected period.
- Last close
- $5.51
- Period change
- -34.01%
- Period low
- $5.51
- Period high
- $8.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $6.06 | $6.16 | $5.25 | $5.51 | 275.05K |
| Sep 14, 2026 | $6.28 | $6.395 | $6.06 | $6.11 | 307.73K |
| Sep 11, 2026 | $6.49 | $6.49 | $6.21 | $6.34 | 268.77K |
| Sep 10, 2026 | $6.32 | $6.51 | $6.1315 | $6.51 | 242.83K |
| Sep 9, 2026 | $6.37 | $6.51 | $6.13 | $6.47 | 259.53K |
| Sep 8, 2026 | $6.50 | $6.79 | $6.20 | $6.48 | 254.36K |
| Sep 4, 2026 | $6.58 | $6.77 | $6.36 | $6.54 | 231.15K |
| Sep 3, 2026 | $6.84 | $6.93 | $6.28 | $6.60 | 226.58K |
| Sep 2, 2026 | $7.14 | $7.1577 | $6.615 | $6.85 | 228.32K |
| Sep 1, 2026 | $7.32 | $7.3999 | $6.76 | $7.22 | 273.87K |
| Aug 31, 2026 | $7.50 | $7.76 | $7.0821 | $7.30 | 279.21K |
| Aug 28, 2026 | $7.72 | $7.915 | $7.35 | $7.67 | 252.35K |
| Aug 27, 2026 | $7.70 | $8.00 | $7.48 | $7.78 | 277.03K |
| Aug 26, 2026 | $7.85 | $8.27 | $7.41 | $7.72 | 278.21K |
| Aug 25, 2026 | $7.91 | $8.40 | $7.5505 | $7.83 | 234.16K |
| Aug 24, 2026 | $6.77 | $8.98 | $6.6409 | $7.90 | 268.86K |
| Aug 21, 2026 | $7.20 | $7.35 | $6.61 | $6.81 | 79.25K |
| Aug 20, 2026 | $7.82 | $7.82 | $7.22 | $7.33 | 44.35K |
| Aug 19, 2026 | $7.92 | $8.40 | $7.65 | $7.75 | 86.37K |
| Aug 18, 2026 | $8.50 | $8.6625 | $7.93 | $8.35 | 92.82K |
Latest NNNN news
The latest Smart Investors Daily articles mentioning NNNN.
Stock researchResearch & News · Competitors
Loading stock research…